Clinical evidence with montelukast in the management of chronic childhood asthma

Drugs

Volumn 59, Issue SUPPL. 1, 2000, Pages 29-34

  Becker, Allan ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALLERGEN; ASPARTATE AMINOTRANSFERASE; BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; COLLAGENASE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; LEUKOTRIENE; LEUKOTRIENE D4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; NEDOCROMIL; PRANLUKAST; SALBUTAMOL; SALMETEROL; ZAFIRLUKAST;

ALLERGIC RHINITIS; ASTHMA; CHILD; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EXERCISE INDUCED ASTHMA; FORCED EXPIRATORY VOLUME; HUMAN; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

EID: 0034085977     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200059001-00005     Document Type: Review

References (42)

1. Kellaway CH, Trethewie ER. The liberation of a low-reading smooth muscle-stimulating substance in anaphylaxis. Q J Exp Physiol 1940; 30: 121-45
2. Brocklehurst W. The release of histamine and formation of a slow reacting substance (SRS-A) during anaphylactic shock. J Physiol 1960; 151: 416-35
3. Kaiser E, Chiba P, Zaky K. Phospholipases in biology and medicine. Clin Biochem 1990; 20: 217-23
4. Griffin M, Weiss JW, Leitch AG, et al. Effects of leukotriene D on the airways in asthma. N Engl J Med 1983; 308: 436-9
5. Marom Z, Shekhamer JH, Bach MK, et al. Slow-reacting substances leukotrienes C4 and D4 increase the release of mucus from human airways in vitro. Am Rev Respir Dis 1982; 126: 449-51
6. Peck MJ, Piper PJ, Williams TJ. The effect of leukotrienes C4 and D4 on the microvasculation of guinea pig skin. Prostaglandins 1981; 21: 315-21
7. 4 induces MMP-I, which functions as an IGFBP protease in human airway smooth muscle cells. Am J Physiol 271 (Lung Cell Mol Physiol 15): L1014-22
8. 4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet 1989; 1: 584-8
9. 4 levels during early and late asthmatic responses. J Allergy Clin Immunol 1990; 86: 211-20
10. Manning PJ, Watson RM, Margolskee DJ, et al. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist. N Engl J Med 1990; 323: 1736-9
11. 4 after exercise challenge in children with asthma. J Allergy Clin Immunol 1992; 89: 1111-9
12. Sampson AP, Castling DP, Green CP, et al. Persistent increase in plasma and urinary leukotrienes after acute asthma. Arch Dis Child 1995; 73: 221-5
13. Smith LJ, Geller J, Elbright L, et al. Inhibition of leukotriene D4-induced bronchoconstriction in normal subjects by the oral./D4 receptor antagonists ICI 204,219. Am Rev Respir Dis 1990; 141: 988-92
14. Wahedna I, Wisniewski AS, Tattersfield AE. Effect of RG 12525, an oral leukotriene D4 antagonist, on the airway response to inhaled leukotriene D4 in subjects with mild asthma. Br J Clin Pharmacol 1991; 32: 512
15. Dahlen B, Kumlin M, Margolskee DJ, et al. The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics. Eur Respir J 1993; 6: 1018-26
16. Dahlen B, Zetterström O, Björck T, et al. The leukotriene-antagonist ICI-204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics. Eur Respir J 1994; 7: 324-31
17. Diamant Z, Timmers MC, van der Veen H, et al. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. J Allergy Clin Immunol 1995; 95 (1 Pt 1): 42-51
18. Anderson SD. Is there a unifying hypothesis for exercise-induced asthma? J Allergy Clin Immunol 1984; 73: 660-5
19. McFadden Jr ER. Exercise-induced airway obstruction. Clin Chest Med 1995; 16: 671-82
20. Randolph C. Exercise-induced asthma: update on pathophysiology, clinical diagnosis and treatment. Curr Probl Pediatr 1997; 27: 53-77
21. Manning PJ, Watson RM, Margolskee DJ, et al. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist. N Engl J Med 1990; 232: 1736-9
22. 4 receptor antagonist ICI 204,219 against exercise-induced asthma. Am Rev Respir Dis 1993; 147: 1413-8
23. Kemp JP, Dockhorn RJ, Shapiro GG, et al. Montelukast, once daily inhibits exercise-induced bronchoconstriction in 6-to 14-year-old children with asthma. J Pediatr 1998; 133 (3): 424-8
24. de Benedictis FM, Tuteri G, Pazzelli P, el al. Cromolyn versus nedocromil: duration of action in exercise-induced asthma in children. J Allergy Clin Immunol 1995; 96: 510-4
25. Berkowitz R, Schwartz E, Bukstein MD, et al. Albuterol protects against exercise-induced asthma longer than metaproterenol sulfate. Pediatrics 1986; 77 (2): 173-8
26. Green CP, Price JF. Prevention of exercise induced asthma by inhaled salmeterol xinafoate. Arch Dis Child 1992; 67: 1014-7
27. Simons FER, Gerstner TV, Cheang MS. Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics 1997; 99 (5): 655-9
28. Leff JA, Busse WW, Pearlman D, et al. Montelukast, a leukotriene receptor antagonist, for treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998; 339: 147-52
29. Turpin JA, Edelman JM, DeLucca PT, et al. Chronic administration of montelukast (MK-476) is superior to inhaled salmeterol in the prevention of exercise-induced bronchoconstriction(EIB) Am J Respir Crit Care Med 1998; 157: A456
30. Villaran C, O'Neill S, Helbling A, et al. Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. J Allergy Clin Immunol 1999; 104 (3 Pt 1): 547-53
31. Edelman JM, Turpin JA, DeLucca PT. The Exercise Study Group: Merck & Co., Inc., Horsham, PA, United States. Comparison of oral montelukast, a leukotriene antagonist and inhaled salmeterol in exercise induced asthma (EIA). Eur Respir J 1998; 12: 18s
32. Knorr B, Matz J, Bernstein J, et al. Montelukast for chronic asthma in 6-to 14-year-old children. JAMA 1998; 279 (15); 1181-6
33. Juniper EF, Guyatt GH, Feeny D, et al. Measuring the quality oflife in children with asthma. Qual Life Res 1996; 5: 35-46
34. Pizzichini E, Leff JA, Reiss TF, et al. Montelukast reduces airway inflammation in asthma: a randomized controlled trial. Eur Resp J 1999; 14: 12-8
35. Seidenberg BC, Reiss TE. Montelukast - an antileukotriene treatment for asthma. In: Drazen JM, Dahlèn SE, Lee, TH, editors. Five-lipoxygenase products in asthma. New York, NY: Marcel Dekker Inc., 1998: 327-46
36. Noonan G, Reiss TF, Shingo S, et al. Montelukast (MK-0476) maintains long-term asthma control in adults and pediatric patients (aged &ge6 years). Am J Respir Crit Care Med 1999; 159: A640
37. Knorr BA, Matz J, Sveum RJ, et al. Montelukast (MK-0476) improves asthma over 6 months of treatment in 6-to 14-year-old patients. Eur Respir J 1997; 10: 219S
38. Edelman JM, Preston SR, Turpin JA, et al. Parent and child preference for montelukast, a leukotriene receptor antagonist, compared to inhaled cromolyn in asthmatic children ages 6 to 11. Eur Respir J 1998; 12: 18s
39. Edelman JM, Milewski KA, Turpin JA, et al. Effectiveness and safety of montelukast, a leukotriene receptor antagonist, compared to inhaled cromolyn in moderate asthmatic children ages 6 to 11. J Allergy Clin Immunol 1999; 103: S134
40. Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. Ann Intern Med 1999; 130 (6); 487-95
41. Tamaoki J, Kondo M, Sakai N, et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-close inhaled corticosteroid. Am J Crit Care Med 1997; 155: 1235-40
42. Lofdahl GG, Reiss TF, Leff JA, et al. Randomised, placebo-controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ 1999; 319: 87-90